UBS’s $25 target on AMRX

AMRX Amneal Pharmaceuticals Inc Class a

$20.1 → $25 (+25%) by Oct 2027

Buy · reiterates · said Oct 1, 2026 · 12-month default horizon

Open: judged on the close on Oct 1, 2027

The article this target came from

Investing.com · Oct 1, 2026

UBS reiterates Amneal Pharmaceuticals stock Buy rating on HRT growth

A fact about what UBS published, as reported by Investing.com, not a recommendation from Dalsna Finance; UBS is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.